Literature DB >> 24797504

A retrospective study of volume doubling time in surgically resected non-small cell lung cancer.

John A Mackintosh1, Henry M Marshall, Ian A Yang, Rayleen V Bowman, Kwun M Fong.   

Abstract

BACKGROUND AND
OBJECTIVE: Volume doubling time (VDT) contributes to the evaluation of the indeterminate pulmonary nodule, an increasingly frequent problem given the rising use of computed tomography (CT). We aimed to correlate patient and tumour characteristics with VDT and growth rates of primary non-small cell lung cancers (NSCLC).
METHODS: Surgically treated NSCLC, which underwent two or more CT scans separated by 25 or more days were studied. Tumour volume was measured using semi-automated volumetric software. VDT and growth rate (1/VDT) were correlated with patient and tumour characteristics.
RESULTS: Thirty-six adenocarcinomas (AC), six squamous cell carcinoma (SCC), two large cell and two carcinoids in 46 patients had 109 eligible scans. Median VDT was 191 days (range -9435 to 2256 days); median growth rate was 0.0038 (range -0.0086 to 0.0186). Median growth rate of AC was significantly slower than SCC (0.0034 vs. 0.0103, P = 0.037). Nine AC had VDT >400 days, three of which developed distant metastases. Median growth rate of AC was faster in smokers compared with never-smokers (0.0052 vs. 0.0014, P = 0.02). Growth rate was not related to symptoms at diagnosis (P = 0.16). Less differentiated tumours tended to grow faster than more differentiated (P = 0.0038). Growth curves of 12 multi-imaged tumours conformed best with the exponential model of growth.
CONCLUSIONS: NSCLC growth rate appears to be highly variable and related to histological subtype and smoking history, but not the presence of symptoms at diagnosis. Significant growth may be detected in as little as 2 months in NSCLC in smokers. Relatively slow-growing AC can metastasize.
© 2014 Asian Pacific Society of Respirology.

Entities:  

Keywords:  adenocarcinoma; lung neoplasm; non-small cell lung cancer; time factor; tomography

Mesh:

Year:  2014        PMID: 24797504     DOI: 10.1111/resp.12311

Source DB:  PubMed          Journal:  Respirology        ISSN: 1323-7799            Impact factor:   6.424


  12 in total

1.  Volume doubling time of lung cancer detected in idiopathic interstitial pneumonia: comparison with that in chronic obstructive pulmonary disease.

Authors:  Cherry Kim; Sang Min Lee; Jooae Choe; Eun Jin Chae; Kyung-Hyun Do; Joon Beom Seo
Journal:  Eur Radiol       Date:  2017-10-16       Impact factor: 5.315

2.  Thymidine phosphorylase affects clinical outcome following surgery and mRNA expression levels of four key enzymes for 5-fluorouracil metabolism in patients with stage I and II non-small cell lung cancer.

Authors:  Naoya Himuro; Yumiko Niiya; Takao Minakata; Yutaka Oshima; Daisuke Kataoka; Shigeru Yamamoto; Takashi Suzuki; Mitsutaka Kadokura
Journal:  Mol Clin Oncol       Date:  2018-09-25

3.  The impact of histology and ground-glass opacity component on volume doubling time in primary lung cancer.

Authors:  Kai Obayashi; Kimihiro Shimizu; Seshiru Nakazawa; Toshiteru Nagashima; Toshiki Yajima; Takayuki Kosaka; Jun Atsumi; Natsuko Kawatani; Tomohiro Yazawa; Kyoichi Kaira; Akira Mogi; Hiroyuki Kuwano
Journal:  J Thorac Dis       Date:  2018-09       Impact factor: 2.895

4.  Correlation Factors Analysis of Breast Cancer Tumor Volume Doubling Time Measured by 3D-Ultrasound.

Authors:  Shuyin Zhang; Yan Ding; Qiaoying Zhou; Cheng Wang; Pengxi Wu; Ji Dong
Journal:  Med Sci Monit       Date:  2017-06-27

5.  A case of pulmonary adenocarcinoma showing rapid progression of peritoneal dissemination after immune checkpoint inhibitor therapy.

Authors:  Taro Shinozaki; Eri Iwami; Shinnosuke Ikemura; Tatsu Matsuzaki; Takahiro Nakajima; Kazuhiko Hashimoto; Takeshi Terashima
Journal:  BMC Cancer       Date:  2018-05-31       Impact factor: 4.430

6.  Malignancy risk estimation of pulmonary nodules in screening CTs: Comparison between a computer model and human observers.

Authors:  Sarah J van Riel; Francesco Ciompi; Mathilde M Winkler Wille; Asger Dirksen; Stephen Lam; Ernst Th Scholten; Santiago E Rossi; Nicola Sverzellati; Matiullah Naqibullah; Rianne Wittenberg; Marieke C Hovinga-de Boer; Miranda Snoeren; Liesbeth Peters-Bax; Onno Mets; Monique Brink; Mathias Prokop; Cornelia Schaefer-Prokop; Bram van Ginneken
Journal:  PLoS One       Date:  2017-11-09       Impact factor: 3.240

7.  Management of surgical lung cancer patients during the COVID-19 pandemic in the financially and resource strained Greek health care system.

Authors:  Emmanouil I Kapetanakis; Ioannis P Tomos; Anna Karakatsani; Anna Koumarianou; Periklis I Tomos
Journal:  J Surg Oncol       Date:  2020-05-23       Impact factor: 3.454

8.  Effect of time interval from diagnosis to treatment for non-small cell lung cancer on survival: a national cohort study in Taiwan.

Authors:  Pei-Tseng Kung; Wen-Chen Tsai; Chang-Hung Tsai; Wei-Yin Kuo
Journal:  BMJ Open       Date:  2020-04-22       Impact factor: 2.692

9.  Volume doubling time of lung adenocarcinomas considering epidermal growth factor receptor mutation status of exon 19 and 21: three-dimensional volumetric evaluation.

Authors:  Rui Zhang; Bojiang Chen; Yongzhao Zhou; Ping Zhou; Jing Jin; Longchao Zhao; Weimin Li
Journal:  J Thorac Dis       Date:  2017-11       Impact factor: 2.895

10.  In Silico Oncology: Quantification of the In Vivo Antitumor Efficacy of Cisplatin-Based Doublet Therapy in Non-Small Cell Lung Cancer (NSCLC) through a Multiscale Mechanistic Model.

Authors:  Eleni Kolokotroni; Dimitra Dionysiou; Christian Veith; Yoo-Jin Kim; Jörg Sabczynski; Astrid Franz; Aleksandar Grgic; Jan Palm; Rainer M Bohle; Georgios Stamatakos
Journal:  PLoS Comput Biol       Date:  2016-09-22       Impact factor: 4.475

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.